These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 1756252)

  • 41. Efficacy and safety of rVIII-SingleChain: results of a phase 1/3 multicenter clinical trial in severe hemophilia A.
    Mahlangu J; Kuliczkowski K; Karim FA; Stasyshyn O; Kosinova MV; Lepatan LM; Skotnicki A; Boggio LN; Klamroth R; Oldenburg J; Hellmann A; Santagostino E; Baker RI; Fischer K; Gill JC; P'Ng S; Chowdary P; Escobar MA; Khayat CD; Rusen L; Bensen-Kennedy D; Blackman N; Limsakun T; Veldman A; St Ledger K; Pabinger I;
    Blood; 2016 Aug; 128(5):630-7. PubMed ID: 27330001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relationship between factor VII activity and clinical efficacy of recombinant factor VIIa given by continuous infusion to patients with factor VIII inhibitors.
    Santagostino E; Morfini M; Rocino A; Baudo F; Scaraggi FA; Gringeri A
    Thromb Haemost; 2001 Oct; 86(4):954-8. PubMed ID: 11686352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Comparative effectiveness of full-length and B-domain deleted factor VIII for prophylaxis--a meta-analysis.
    Gruppo RA; Brown D; Wilkes MM; Navickis RJ
    Haemophilia; 2003 May; 9(3):251-60. PubMed ID: 12694514
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics.
    Kulkarni R; Karim FA; Glamocanin S; Janic D; Vdovin V; Ozelo M; Rageliene L; Carboni E; Laguna P; Dobaczewski G; Seremetis S; Lindblom A; Santagostino E
    Haemophilia; 2013 Sep; 19(5):698-705. PubMed ID: 23651313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Treatment and prevention of acute bleedings in von Willebrand disease--efficacy and safety of Wilate, a new generation von Willebrand factor/factor VIII concentrate.
    Berntorp E; Windyga J;
    Haemophilia; 2009 Jan; 15(1):122-30. PubMed ID: 19149848
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measurement of anti-factor VIII IgG, IgG4 and IgM alloantibodies in previously untreated hemophilia A patients treated with recombinant factor VIII. Kogenate Japanese Clinical Study Group.
    Shima M; Sawamoto Y; Nakai H; Kamisue S; Murakami T; Morichika S; Tanaka I; Hayashi K; Yoshioka A
    Int J Hematol; 1995 Jul; 62(1):35-43. PubMed ID: 7670006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. SHP656, a polysialylated recombinant factor VIII (PSA-rFVIII): First-in-human study evaluating safety, tolerability and pharmacokinetics in patients with severe haemophilia A.
    Tiede A; Allen G; Bauer A; Chowdary P; Collins P; Goldstein B; Jiang HJ; Kӧck K; Takács I; Timofeeva M; Wolfsegger M; Srivastava S
    Haemophilia; 2020 Jan; 26(1):47-55. PubMed ID: 31778283
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epidemiology of inhibitor formation with recombinant factor VIII replacement therapy.
    Peerlinck K; Hermans C
    Haemophilia; 2006 Nov; 12(6):579-90. PubMed ID: 17083507
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intranasal DDAVP induced increases in plasma von Willebrand factor alter the pharmacokinetics of high-purity factor VIII concentrates in severe haemophilia A patients.
    Deitcher SR; Tuller J; Johnson JA
    Haemophilia; 1999 Mar; 5(2):88-95. PubMed ID: 10215955
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Bradshaw S; Hough C; Othman M; Lillicrap D
    Blood; 2009 Jul; 114(4):871-80. PubMed ID: 19411636
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The uptake of recombinant Factor VIII in the Netherlands.
    Zwart-van Rijkom JE; Plug I; Rosendaal FR; Leufkens HG; Broekmans AW;
    Br J Haematol; 2002 Nov; 119(2):332-41. PubMed ID: 12406065
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy, Safety, and Pharmacokinetics of Beroctocog Alfa in Patients Previously Treated for Hemophilia A.
    Hyun SY; Park SY; Lee SY; Kook H; Paik SH; Jang IJ; Lee KS
    Yonsei Med J; 2015 Jul; 56(4):935-43. PubMed ID: 26069114
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy and safety of prophylaxis with once-weekly BAY 79-4980 compared with thrice-weekly rFVIII-FS in haemophilia A patients. A randomised, active-controlled, double-blind study.
    Powell J; Martinowitz U; Windyga J; Di Minno G; Hellmann A; Pabinger I; Maas Enriquez M; Schwartz L; Ingerslev J;
    Thromb Haemost; 2012 Nov; 108(5):913-22. PubMed ID: 23014711
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pharmacokinetic properties of recombinant factor VIII compared with a monoclonally purified concentrate (Hemofil M). The Recombinate Study Group.
    Morfini M; Longo G; Messori A; Lee M; White G; Mannucci P
    Thromb Haemost; 1992 Oct; 68(4):433-5. PubMed ID: 1448776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. OBI-1, porcine recombinant Factor VIII for the potential treatment of patients with congenital hemophilia A and alloantibodies against human Factor VIII.
    Toschi V
    Curr Opin Mol Ther; 2010 Oct; 12(5):617-25. PubMed ID: 20886394
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.
    Iorio A; Halimeh S; Holzhauer S; Goldenberg N; Marchesini E; Marcucci M; Young G; Bidlingmaier C; Brandao LR; Ettingshausen CE; Gringeri A; Kenet G; Knöfler R; Kreuz W; Kurnik K; Manner D; Santagostino E; Mannucci PM; Nowak-Göttl U
    J Thromb Haemost; 2010 Jun; 8(6):1256-65. PubMed ID: 20345722
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recombinant factor VIII: past, present and future of treatment of hemophilia A.
    Raso S; Hermans C
    Drugs Today (Barc); 2018 Apr; 54(4):269-281. PubMed ID: 29869648
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
    Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
    Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of pharmacokinetics, efficacy and safety of Immunate solvent detergent in previously treated patients with severe haemophilia A.
    Nemes L; Lissitchkov T; Klukowska A; Dobaczewski G; Komrska V; Zimmermann R; Auerswald G; Engl W; Pavlova B; Abbühl B; Ehrlich HJ
    Haemophilia; 2007 Jan; 13(1):9-11. PubMed ID: 17212718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Human recombinant DNA-derived antihemophilic factor (factor VIII) in the treatment of hemophilia A.
    Hsu HC; Chen YF; Ho CH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Jul; 62(7):450-4. PubMed ID: 10418180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.